Chemical modification has been performed on an orally bioavailable and potent CCR5 antagonist, sulfoxide compound 4, mainly focusing on replacement of the [6,7]-fused 1-benzazepine nucleus. We designed, synthesized, and evaluated the biological activities of ring-expanded [6,8]-, [6,9]-, and [6,10]-fused compounds containing S-sulfoxide moieties, which led to the discovery of 1-benzazocine and 1-benzazonine compounds that exhibited potent inhibitory activities (equivalent to compound 4) in a binding assay. In addition, 1-benzazocine compounds possessing the S-sulfoxide moiety ((S)-(-)-5a,b,d,e) showed greater potency than compound 4 in a fusion assay. From further investigation in a multi-round infection assay, it was found that 1-isobutyl-1-benzazocine compound (S)-(-)-5b, containing the S-{[(1-propyl-1H-imidazol)-5-yl]methyl}sulfinyl group, showed the most potent anti-HIV-1 activity (IC90=0.81 nM, in MOLT4/CCR5 cells). Compound (S)-(-)-5b (TAK-652) also inhibited the replication of six macrophage-tropic (CCR5-using or R5) HIV-1 clinical isolates in peripheral blood mononuclear cells (PBMCs) (mean IC90=0.25 nM). It was also absorbed after oral administration in rats, dogs, and monkeys and was thus selected as a clinical candidate. The synthesis and biological activity of the 1-benzazocine compound (S)-(-)-5b and its related derivatives are described.

No abstract

Mcl-1 and Bcl-xL are crucial regulators of apoptosis, therefore dual inhibitors of both proteins could serve as promising new anticancer drugs. To design Mcl-1/Bcl-xL dual inhibitors, we performed structure-guided analyses of the corresponding selective Mcl-1 and Bcl-xL inhibitors. A cocrystal structure of a pyrazolo[1,5-a]pyridine derivative with Mcl-1 protein was successfully determined and revealed the protein-ligand binding mode. The key structure for Bcl-xL inhibition was further confirmed through the substructural analysis of ABT-263, a representative Bcl-xL/Bcl-2/Bcl-w inhibitor developed by Abbott Laboratories. On the basis of the structural data from this analysis, we designed hybrid compounds by tethering the Mcl-1 and Bcl-xL inhibitors together. The results of X-ray crystallographic analysis of hybrid compound 10 in complexes with both Mcl-1 and Bcl-xL demonstrated its binding mode with each protein. Following further optimization, compound 11 showed potent Mcl-1/Bcl-xL dual inhibitory activity (Mcl-1, IC50 = 0.088 μM; and Bcl-xL, IC50 = 0.0037 μM).

4,5-Bis(terpyridyl)-2,7-di-tert-butyl-9,9-dimethylxanthene (btpyxa) was prepared to serve as a new bridging ligand via Suzuki coupling of terpyridin-4'-yl triflate and 2,7-di-tert-butyl-9,9-dimethylxanthene-4,5-diboronic acid. The reaction of btpyxa with either 1 equiv or an excess of PtCl(2)(cod) (cod = 1,5-cyclooctadiene) followed by anion exchange afforded mono- and dinuclear platinum complexes [(PtCl)(btpyxa)](PF(6)) ([1](PF(6))) and [(PtCl)(2)(btpyxa)](PF(6))(2) ([2](PF(6))(2)), respectively. The X-ray crystallography of [1](PF(6)).CHCl(3) revealed that the two terpyridine units in the ligand are nearly parallel to each other. The heterodinuclear complex [(PtCl)[Ru((t)Bu(2)SQ)(dmso)](btpyxa)](PF(6))(2) ([4](PF(6))(2)) (dmso = dimethyl sulfoxide; (t)Bu(2)SQ = 3,5-di-tert-butyl-1,2-benzosemiquinone) and the monoruthenium complex [Ru((t)Bu(2)SQ)(dmso)(trpy)](PF(6)) ([5](PF(6))) (trpy = 2,2':6',2' '-terpyridine) were also synthesized. The CV of [2](2+) suggests possible electronic interaction between the two Pt(trpy) groups, whereas such an electronic interaction was not suggested by the CV of [4](2+) between Pt(trpy) and Ru((t)Bu(2)SQ) frameworks.